Stay updated on M7824 for Stage II-III HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the M7824 for Stage II-III HER2+ Breast Cancer Clinical Trial page.

Latest updates to the M7824 for Stage II-III HER2+ Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe webpage has been updated to include new classifications and identifiers related to breast cancer studies, while significant details about a specific clinical trial involving the anti-PD-L1/TGFbetaRII fusion protein M7824 have been removed.SummaryDifference55%
- Check54 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check97 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check111 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to M7824 for Stage II-III HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 for Stage II-III HER2+ Breast Cancer Clinical Trial page.